Ultragenyx Pharmaceutical | RARE - Cost Of Sales


Ultragenyx Pharmaceutical reported $30M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Kyowa Hakko Kirin JPY 33B 4.87B Mar/2026
MacroGenics USD 10.12M 34.18M Dec/2025
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Xoma 116K 112.7K Jun/2024